SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76: 16717.
  • 2
    Yamamoto M, Ohashi O, Saitoh Y. Japan Pancreatic Cancer Registry: current status. Pancreas 1998;16: 23842.
  • 3
    Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–95, using the National Cancer Database. J Am Coll Surg 1999;189: 17.
  • 4
    Evans DB, Jessup JM, Colacchio T. Pancreatic cancer surgical practice guidelines. Pancreas Cancer Practice Guideline Committee. Oncology (Huntington) 1997; 11: 10749.
  • 5
    Kornek GV, Schratter-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, Haider K, Kwasny W, Locker G, Scheithauer W. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 2000;82: 98103.
  • 6
    Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared to resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89: 31427.
  • 7
    Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225: 62136.
  • 8
    Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223: 2739.
  • 9
    National Cancer Institute. Annual cancer statistics review 1973–88. NIH Publication No.91-2789. Bethesda, MD: Department of Health and Human Services, 1991.
  • 10
    Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G. Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102: 2306.
  • 11
    Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16: 777382.
  • 12
    Kawesha A, Ghaneh P Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89: 46974.
  • 13
    Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996;56: 4904.
  • 14
    Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero RA Jr, et al. DPC4 gene in various tumor types. Cancer Res 1996;56: 252730.
  • 15
    Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271: 3503.
  • 16
    Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156: 3743.
  • 17
    Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88: 223945.
  • 18
    Sonoda K, Nakashima M, Kaku T, Kamura T, Nakano H, Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996;77: 15019.
  • 19
    Kaku T, Sonoda K, Kamura T, Hirakawa T, Sakai K, Amada S, Ogawa S, Kobayashi H, Nakashima M, Watanabe T, Nakano H. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin Cancer Res 1999;5: 144953.
  • 20
    Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y, Yamanaka H, Matsumura A, Iuchi K, Mori T, Okada M. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000;89: 48893.
  • 21
    Izumi M, Nakanishi Y, Yoshino I, Nakashima M, Watanabe T, Hara N. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001;92: 44651.
  • 22
    Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin Cancer Res 1998;4: 151720.
  • 23
    Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5: 93842.
  • 24
    SobinLH, Wittekind Ch, editors. UICC TNM classification of malignant tumors. 5th ed. New York: John Wiley and Sons, Inc., 1997.
  • 25
    Melero I, Bach N, Chen L. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci 1997;60: 203541.
  • 26
    Thomas GR, Chen Z, Oechsli MN, Hendler FJ, Van Waes C. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer 1999;82: 37784.
  • 27
    Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001;61: 15007.
  • 28
    Goodenow RS, Vogel JM, Linsk RL. Histocompatibility antigens on murine tumors. Science 1985;230: 77783.
  • 29
    Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177: 26572.
  • 30
    Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 1996;2: 13616.
  • 31
    Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274: 13636.
  • 32
    Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998;58: 17419.
  • 33
    Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1. Cancer Res 1992;52: 138692.
  • 34
    Sonoda K, Kaku T, Hirakawa T, Kobayashi H, Amada S, Sakai K, Nakashima M, Watanabe T, Nakano H. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic and malignant uterine endometrium. Gynecol Oncol 2000;79: 4249.
  • 35
    Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57: 17314.
  • 36
    Kozuka S, Sassa R, Taki T, Masamoto K, Nagasawa S, Saga S, Hasegawa K, Takeuchi M. pancreatic duct hyperplasia to carcinoma. Cancer 1979;43: 141828.
  • 37
    Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22: 1639.
  • 38
    Haisma HJ, Pinedo HM, Rijswijk A, der Meulen-Muileman I, Sosnowski BA, Ying W, Beusechem VW, Tillman BW, Gerritsen WR, Curiel DT. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999;6: 146974.
  • 39
    Kelly FJ, Miller CR, Buchsbaum DJ, Gomez-Navarro J, Barnes MN, Alvarez RD, Curiel DT. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells vs. autologous mesothelial cells in vitro. Clin Cancer Res 2000;6: 432333.
  • 40
    DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994;116: 20513.
  • 41
    Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995;55: 31059.
  • 42
    Kaneko S, Hallenbeck P, Kotani T, Nakabayashi H, McGarrity G, Tamaoki T, Anderson WF, Chiang YL. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995;55: 52837.
  • 43
    Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Katoh H, Kuzumaki N. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000;7: 51826.